ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing neffy (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions, including food, medications, and insect bites that could lead to anaphylaxis. The firm has designed and developed neffy to provide injection-like absorption of epinephrine, at a low dose, easy-to-use small nasal spray device.